Using CAR T-cell therapies for blood cancer should be less burdensome following labeling updates.
Using chimeric antigen receptor T-cell therapies for blood cancer should be less burdensome following labeling updates from the FDA. Specifically, the FDA removed the Risk Evaluation and Mitigation Strategy program requirements from two BCMA-directed CAR T -cell therapies forto Janssen explaining the move, the agency said that “the established management guidelines and extensive experience of the medical hematology/oncology community in diagnosing and managing the risks of and neurologic toxicities across products in the class of BCMA- and CD19-directed autologous CAR T cell immunotherapies” means that REMS programs are no long necessary to ensure safe use.
The agency further streamlined the labels of the two BMS therapies by reducing requirements to stay near a health facility after treatment from 4 to 2 weeks and by dropping driving restrictions after treatment from 8 to 2 weeks., BMS applauded the “class-wide label updates that will help ease known barriers to treatment and administration while maintaining patient safety.” The company also noted that recent studies have made it clear that the “vast majority of serious adverse events” with CAR T-cell therapy occur within the first 2 weeks of infusion. “Today’s announcement reduces some of the most onerous requirements that may have previously discouraged patients, particularly those who live far from a treatment center, from seeking the potentially transformational effects of cell therapy,” saidM. Alexander Otto is a physician assistant with a master’s degree in medical science and a journalism degree from Newhouse. He is an award-winning medical journalist who worked for several major news outlets before joining Medscape. Alex is also an MIT Knight Science Journalism fellow. Email:Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our
Biologics Chimeric Antigen Receptor T-Cell Therapy Chimeric Antigen Receptors Chimeric Immunoreceptors Chimeric T-Cell Receptors Artificial T-Cell Receptors CAR T Chimaeric Antigen Receptor T-Cell Therapy Chimaeric Antigen Receptors Chimaeric Immunoreceptors Chimaeric T-Cell Receptors Leukemia Leukaemia Blood Cancer
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Henry Ford Museum seeks vintage car mechanic | Car NewsThe Henry Ford Museum is looking for a vintage car mechanic to maintain and service its vehicle fleet.
Read more »
How Tariffs Will Affect Used Car Prices: Car Salesman ConfidentialOur car sales expert on how the Trump administration’s tariffs on imported new cars and parts will affect used car prices.
Read more »
Smart infant car seat created by LSU students aims to prevent hot car fatalitiesIn response to heartbreaking tragedies, a team of graduates from LSU creates a smart car seat designed to prevent children from dying in hot vehicles.
Read more »
the world's biggest car factory where a car is made every 10 secondsThe Korean brand's factory is the world’s largest car-making facility, with five separate factories and an on-site port
Read more »
the world's biggest car factory where a car is made every 10 secondsThe Korean brand's factory is the world’s largest car-making facility, with five separate factories and an on-site port
Read more »
Electric Car: 2025 Car Ranking | Car NewsDiscover our exclusive ranking of electric cars for 2025. Explore the Hyundai KONA Electric and other leading vehicles
Read more »